Last reviewed · How we verify
Phenytoin (Vega Baja) (phenytoin-vega-baja)
Phenytoin (Vega Baja) is a small-molecule aromatic antiepileptic drug (AED) developed by Pfizer, currently in Phase 1 clinical development. The drug works by stabilizing neuronal membranes and reducing excessive electrical activity in the brain through modulation of voltage-gated sodium channels, a well-established mechanism in seizure management. Phenytoin has a long clinical history as an approved seizure treatment, though this Vega Baja formulation appears to represent a development program examining bioavailability or pharmacokinetic properties of different pharmaceutical forms. The Phase 1 trial (N=35, completed) evaluated absorption kinetics in healthy volunteers, suggesting a focus on optimizing drug delivery or formulation characteristics. As a reformulation of an established generic drug, commercial differentiation will depend on demonstrating superior bioavailability, reduced variability, or improved tolerability compared to existing phenytoin products. Phenytoin remains a foundational AED globally, though newer agents have captured significant market share; this development may target niche indications or populations with specific formulation needs.
At a glance
| Generic name | phenytoin-vega-baja |
|---|---|
| Sponsor | Pfizer Inc. |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Phenytoin (Vega Baja) CI brief — competitive landscape report
- Phenytoin (Vega Baja) updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI